Researchers at the National University of Singapore (NUS) have built a battery-free implant that draws its power from the body's own blood sugar and stimulates the vagus nerve whenever glucose climbs too high. In a paper published in the journal Nature on 18 November 2026, the team reports that the device, called NeuroAxis, restored normal blood-sugar control in rat models of both type 1 and type 2 diabetes. The work has so far been tested only in animals.
What does the device do?
NeuroAxis senses rising glucose and responds by electrically stimulating the vagus nerve, the main nerve linking the brain with the internal organs. The authors describe it as an "artificial neuroimmune axis": it is meant to copy a natural reflex in which the vagus nerve helps dampen inflammation and keep metabolism in balance.
Two features set it apart, according to the paper. First, it is powered solely by glucose already present in the body, through a glucose fuel cell, so it needs neither a battery nor wireless charging. Second, it works as a closed loop. The paper's supplementary material says stimulation is triggered only after glucose readings stay above a set threshold for five consecutive readings; the implant then delivers biphasic electrical pulses for three minutes.
What did the rat experiments show?
The researchers report that, in rats with type 1 diabetes, the implant helped insulin-producing beta cells in the pancreas recover and reduced inflammatory immune responses. In rats with type 2 diabetes, it reshaped immune cells called macrophages and reduced chronic inflammation throughout the body.
In both models, the paper says, NeuroAxis restored glucose tolerance, improved the body's sensitivity to insulin and normalised blood-sugar control. The authors add that the benefits persisted after the treatment was stopped. The study also examined tissue around the implant site, including the oesophagus and abdominal skin, after eight weeks of implantation.
Why does it matter?
Diabetes develops when insulin, the hormone made by pancreatic beta cells, can no longer keep blood glucose at healthy levels. Writing in an accompanying Nature News & Views commentary, Junta Imai of the Tohoku University Graduate School of Medicine in Sendai, Japan, notes that hundreds of millions of people worldwide live with the condition and that constantly managing diet, medication and glucose readings can impair quality of life. He describes the study as a proof of principle for a device that monitors and controls blood sugar automatically.
For readers in India, where diabetes is a major public-health concern, the work points to a possible future treatment route that does not rely on daily pills or injections. It is not, however, a therapy anyone can use today.
What is not yet known?
- The device has been tested only in rats; no human data have been reported.
- The paper does not establish long-term safety or how long such an implant would keep working in people.
- Whether the effects seen in rat models of type 1 and type 2 diabetes will translate to patients remains to be tested.
What happens next?
The authors say the approach could serve as a general way to regulate communication between organs. Any move towards clinical use would require further safety studies and, eventually, human trials, none of which have been announced.
Photo source · Roy Zuo, CC BY-SA 4.0


